Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

Front Immunol. 2023 Jan 11:13:1065379. doi: 10.3389/fimmu.2022.1065379. eCollection 2022.

Abstract

Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future.

Keywords: cervical cancer; cisplatin; ercc1; mechanism; survival.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cervix Uteri / metabolism
  • Cisplatin / therapeutic use
  • DNA-Binding Proteins / metabolism
  • Endonucleases / genetics
  • Endonucleases / metabolism
  • Female
  • Humans
  • Uterine Cervical Neoplasms* / genetics
  • Uterine Cervical Neoplasms* / metabolism
  • Uterine Cervical Neoplasms* / therapy

Substances

  • Cisplatin
  • Endonucleases
  • ERCC1 protein, human
  • DNA-Binding Proteins

Grants and funding

This work was supported by the grants from the Science and Technology Planning Project of Guangzhou (No. 201904010401) and the Science and Technology Project of Panyu District, Guangzhou (No. 2020-Z04-006).